Infantile Neuronal Ceroid Lipofuscinosis

Acronym

Definition

INCL

Including

INCL

Include

INCL

Inclusive

INCL

Inclination

INCL

Infantile Neuronal Ceroid Lipofuscinosis (degenerative illness)

INCL

Insurance, Negligence and Compensation Law (New York State Bar Association)

References in periodicals archive	?		Acronyms browser	?		Full browser	?
Significant recent events in 2009 included: * In January 2009, we completed the six-patient Phase I clinical trial of our HuCNS-SC[R] product candidate as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL), also often referred to as Batten disease. StemCells Announces 2009 First Quarter Financial Results by Business Wire In January 2008, the Company completed enrollment and dosing of a six-patient Phase I clinical trial of its proprietary HuCNS-SC([R]) product candidate (purified human neural stem cells) as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL, also often referred to as Batten disease) at Oregon Health & Science University (OHSU) Doernbecher Children's Hospital. StemCells Announces 2008 First Quarter Results by Business Wire Highlights for 2007 and significant events since the end of the year include: * In January 2008, we completed enrollment and dosing of a six-patient Phase I clinical trial of our HuCNS-SC([R]) product candidate (purified human neural stem cells) as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL, also often referred to as Batten disease) at Oregon Health & Science University (OHSU) Doernbecher Children's Hospital. StemCells Announces 2007 Fourth Quarter and Year End Results by Business Wire	INESC INESOR INESP INESS INEST INESTENE INET INETA INETD INETER INETI INETMOD INEWAM INEWS INEWS/ICNIA INEWSS INEX INF INF_SVC INFA INFAC INFACT iNFADS INFAI INFANT Infantile Neuronal Ceroid Lipofuscinosis INFARMED INFASA INFB INFBD INFC INFCA INFCE INFCEP INFCI INFCIRC INFCO INFCTRL INFCU INFD INFDC INFDT/TS INFE INFEDOP INFEO INFER INFERNO INFF INFFS INFG INFH	infantile giantism infantile giantism infantile glaucoma infantile glaucoma infantile glaucoma infantile hemiplegia infantile hydrocele Infantile Hypercalcaemia/Williams-Beuren Syndrome Infantile hypercalcemia Infantile hypercalcemia infantile hypertrophic gastric stenosis infantile hypertrophic gastric stenosis infantile hypertrophic gastric stenosis Infantile Hypertrophic Pyloric Stenosis Infantile Hypotonia Infantile Hypotonia Infantile Hypotonia Infantile Idiopathic Nephrotic Syndrome infantile lobar emphysema infantile lobar emphysema infantile lobar emphysema infantile massive s infantile massive s infantile massive s infantile muscular atrophy Infantile myoclonic encephalopathy infantile myofibromatosis infantile neuroaxonal dystrophy infantile neuroaxonal dystrophy infantile neuroaxonal dystrophy Infantile Neuronal Ceroid Lipofuscinosis infantile osteomalacia infantile paralysis infantile paralysis infantile paralysis infantile paralysis infantile pellagra infantile pelvis infantile pelvis infantile pelvis Infantile Perianal Pyramidal Protrusion infantile poliomyelitis Infantile polyarteritis Infantile polyarteritis Infantile Polyarthritis Infantile Polycystic Kidney Disease Infantile polycystic kidneys Infantile polycystic kidneys infantile progressive spinal muscular atrophy infantile purulent conjunctivitis infantile pustular dermatosis infantile pustular dermatosis infantile pustular dermatosis Infantile Refractory Grand Mal Syndrome Infantile Refsum disease Infantile Refsum disease Infantile Refsum disease Infantile rose infantile s infantile s infantile s

References in periodicals archive

Acronyms browser

Full browser

Significant recent events in 2009 included: * In January 2009, we completed the six-patient Phase I clinical trial of our HuCNS-SC[R] product candidate as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL), also often referred to as Batten disease.

StemCells Announces 2009 First Quarter Financial Results by Business Wire

In January 2008, the Company completed enrollment and dosing of a six-patient Phase I clinical trial of its proprietary HuCNS-SC([R]) product candidate (purified human neural stem cells) as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL, also often referred to as Batten disease) at Oregon Health & Science University (OHSU) Doernbecher Children's Hospital.

StemCells Announces 2008 First Quarter Results by Business Wire

Highlights for 2007 and significant events since the end of the year include: * In January 2008, we completed enrollment and dosing of a six-patient Phase I clinical trial of our HuCNS-SC([R]) product candidate (purified human neural stem cells) as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL, also often referred to as Batten disease) at Oregon Health & Science University (OHSU) Doernbecher Children's Hospital.

StemCells Announces 2007 Fourth Quarter and Year End Results by Business Wire